BioSpace News Archive

DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced that it has received a listing extension from the Staff of the Listing Qualifications Department of The Nasdaq Capital Market LLC (Nasdaq). The extension grants

Collaboration focuses on developing novel protein replacement and mRNA therapies and explores the targeted delivery of these payloads using Evox’s proprietary exosome technology Partnership encompasses up to five rare disease targets, including Evox’s Niemann-Pick Type C programme, with Takeda assuming responsibility for its clinical development [26-March-2020]

Bolt Biotherapeutics, Inc., a private biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the immune system to treat cancer, today announced that patient dosing has begun

New drugs need to be tested in clinical trials to be approved. However, a recent survey shows that investigators conducting clinical trials on a wide range of diseases are experiencing significant interruptions in their trials due to the ongoing coronavirus crisis.

Management Team to Host Conference Call on March 30, 2020 at 4:30 p.m. ET / 1:30 p.m. PT

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), announces that its global intellectual property portfolio has increased to 49 issued patents and 86 patent applications, including the recent granting and filing of patent applications directed at innovative robotic surgery technologies.

Reaffirms Second Quarter 2020 Expected Timing for Topline Data from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten and Phase 2a Danicamtiv Study

Technology-enabled adherence service tailors asynchronous virtual visit platform to monitor and support healthcare professionals who have been exposed to COVID-19

Cerus Corporation (Nasdaq: CERS) announced today that it has formed a collaborative research group with the aim of optimizing convalescent plasma therapy for COVID-19 patients. The research group seeks to define the key characteristics that influence the efficacy of convalescent plasma, including the level and nature of anti-COVID-19 antibodies, optimal collection timing, dosing and how these influence responses to the

SeptiCyte® RAPID can swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis